What is the elimination half‑life of Lexapro (escitalopram) and the recommended tapering schedule after stopping it?

Lexapro (Escitalopram): Half-Life and Tapering Recommendations

Lexapro has an elimination half-life of 27-32 hours, and when discontinuing, a gradual dose reduction over weeks to months is strongly recommended rather than abrupt cessation, with tapering extending to doses far below minimum therapeutic levels to minimize withdrawal symptoms.

Pharmacokinetic Profile

Elimination Half-Life:

• Escitalopram has a mean terminal half-life of 27-32 hours 1, 2
• Steady-state plasma concentrations are achieved within approximately one week of once-daily dosing 1
• In elderly patients (≥65 years), the half-life increases by approximately 50% 1

Discontinuation Syndrome Risk

Clinical Significance:

• Discontinuation syndrome occurs in approximately 46-56% of patients stopping escitalopram 3, 4
• Common withdrawal symptoms include dizziness (44%), muscle tension (44%), chills (44%), confusion (40%), amnesia (28%), and crying (28%) 3
• Higher doses and plasma concentrations significantly increase the risk of discontinuation syndrome 3
• Symptoms can persist for days to months, with different symptoms having variable durations 5

Important Caveat: While escitalopram/citalopram has relatively less propensity for discontinuation syndrome compared to shorter-acting SSRIs like paroxetine, sertraline, and fluvoxamine 6, it still requires careful tapering 3, 5.

FDA-Approved Tapering Guidance

Official Recommendation:

• The FDA label explicitly states: "A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" 1
• Patients should be monitored for discontinuation symptoms when stopping treatment 1
• If intolerable symptoms occur, resuming the previously prescribed dose should be considered, followed by decreasing at a more gradual rate 1

Evidence-Based Tapering Strategies

Duration and Approach:

Conventional guidelines recommend tapering over 10-14 days 7, but this approach shows minimal benefit over abrupt discontinuation and is often poorly tolerated 8, 5.

More effective strategies based on recent evidence:

• Taper over weeks to months, not days 8, 5
• Extend tapering to doses much lower than minimum therapeutic doses (below 10 mg daily) 8, 9
• Use hyperbolic (exponential) dose reductions rather than linear tapers 8, 9, 10
• Hyperbolic tapering reduces the biological effect at serotonin transporters in a linear manner, minimizing withdrawal 8

Critical Pitfall to Avoid:

• Never use alternate-day dosing when tapering escitalopram 11
• Dosing every other day causes pronounced receptor occupancy variation and significantly increases withdrawal risk, even at low doses 11
• This approach cannot be recommended as a prudent tapering strategy 11

Practical Tapering Algorithm

Step 1: Assess Risk Factors

• Higher current doses increase discontinuation syndrome risk 3
• Document baseline symptoms to distinguish withdrawal from relapse 5

Step 2: Initiate Gradual Taper

• Reduce dose by small increments (consider 10% rule: reduce by 10% of current dose every 2-4 weeks) 10
• Continue daily dosing—do not switch to alternate-day administration 11
• Plan for tapering period of weeks to months, not days 8, 5

Step 3: Continue to Very Low Doses

• Taper below the 10 mg minimum therapeutic dose 8, 9
• Final reductions may require liquid formulations or tablet splitting for doses below 5 mg 9

Step 4: Monitor and Adjust

• If withdrawal symptoms emerge, restart the previous dose and taper even more slowly 5
• Provide symptomatic management as needed 5
• Reassure patients that withdrawal symptoms do not indicate relapse of underlying condition 10

Special Populations

Elderly Patients:

• Half-life increases by ~50% in patients ≥65 years 1
• Even slower tapering may be warranted given prolonged elimination 12

Patients on Higher Doses:

• Those on 20 mg daily face significantly higher discontinuation syndrome risk 3
• Require particularly gradual, extended tapers 3, 5

Key Clinical Pearls

• The relatively longer half-life of escitalopram (27-32 hours) compared to paroxetine does not eliminate the need for careful tapering 6, 3
• Standard 2-week tapers are inadequate and show minimal advantage over abrupt cessation 8, 4
• Very slow tapering extending over months is the most effective strategy to minimize withdrawal 8, 9, 10, 5
• Withdrawal symptoms in the final tapering stages should not be automatically interpreted as depression relapse 10